Toronto Dominion Bank boosted its stake in Eli Lilly and Co. (NYSE:LLY) by 75.5% during the third quarter, Holdings Channel reports. The fund owned 54,372 shares of the company’s stock after buying an additional 23,388 shares during the period. Toronto Dominion Bank’s holdings in Eli Lilly and were worth $4,368,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Iowa State Bank purchased a new stake in Eli Lilly and during the second quarter valued at approximately $104,000. PineBridge Investments L.P. boosted its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares during the last quarter. Integrated Wealth Management boosted its stake in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares during the last quarter. Financial Architects Inc boosted its stake in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares during the last quarter. Finally, Cribstone Capital Management LLC purchased a new stake in Eli Lilly and during the second quarter valued at approximately $117,000. 75.11% of the stock is owned by hedge funds and other institutional investors.
Shares of Eli Lilly and Co. (NYSE:LLY) traded up 1.65% during midday trading on Friday, hitting $69.12. 8,620,682 shares of the stock were exchanged. Eli Lilly and Co. has a 12-month low of $64.18 and a 12-month high of $88.16. The firm has a market cap of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28. The stock’s 50 day moving average is $77.17 and its 200 day moving average is $77.97.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The business had revenue of $5.19 billion for the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. Eli Lilly and’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.89 earnings per share. On average, equities research analysts forecast that Eli Lilly and Co. will post $3.55 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be issued a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.
Several analysts have commented on LLY shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $94.00 target price on shares of Eli Lilly and in a research note on Monday, October 3rd. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $89.00 price objective for the company in a research note on Tuesday, September 27th. Goldman Sachs Group Inc. raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $89.00 to $95.00 in a research note on Tuesday, September 27th. Deutsche Bank AG reissued a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, September 20th. Finally, Jefferies Group reissued a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research note on Wednesday, September 14th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $93.73.
In other news, insider Maria A. Crowe sold 2,248 shares of the firm’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.